ASCO: J&J eyes Darzalex convenience, safety boost with subcutaneous win

Right now, the first infusion of Johnson & Johnson multiple myeloma fighter Darzalex can take between seven and eight hours. But data on a new formulation could be a game-changer.

At the American Society of Clinical Oncology annual meeting, the New Jersey drugmaker trumpeted results from a phase 3 study showing that a subcutaneous form of Darzalex could measure up to the original—and with an average injection time of just five minutes.